These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19116377)

  • 1. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
    Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
    Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
    Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W
    Crit Care; 2010; 14(3):R90. PubMed ID: 20487559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
    Ansara AJ; Arif S; Warhurst RD
    Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
    Begelman SM; Baghdasarian SB; Singh IM; Militello MA; Hursting MJ; Bartholomew JR
    J Intensive Care Med; 2008; 23(5):313-20. PubMed ID: 18701526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban anticoagulation in critically ill patients.
    Beiderlinden M; Treschan TA; Görlinger K; Peters J
    Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.
    Kim SC; Tran N; Schewe JC; Boehm O; Wittmann M; Graeff I; Hoeft A; Baumgarten G
    J Cardiothorac Surg; 2015 Feb; 10():19. PubMed ID: 25879883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
    Smythe MA; Koerber JM; Forsyth LL; Priziola JL; Balasubramaniam M; Mattson JC
    Pharmacotherapy; 2009 Sep; 29(9):1073-81. PubMed ID: 19698012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Argatroban for anticoagulation in continuous renal replacement therapy.
    Link A; Girndt M; Selejan S; Mathes A; Böhm M; Rensing H
    Crit Care Med; 2009 Jan; 37(1):105-10. PubMed ID: 19050602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced argatroban doses after coronary artery bypass graft surgery.
    Hoffman WD; Czyz Y; McCollum DA; Hursting MJ
    Ann Pharmacother; 2008 Mar; 42(3):309-16. PubMed ID: 18303137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis.
    Treichl B; Bachler M; Lorenz I; Friesenecker B; Oswald E; Schlimp CJ; Pedross F; Fries D
    Semin Thromb Hemost; 2015 Feb; 41(1):61-7. PubMed ID: 25594496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.
    Reichert MG; MacGregor DA; Kincaid EH; Dolinski SY
    Ann Pharmacother; 2003 May; 37(5):652-4. PubMed ID: 12708939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
    Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
    Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.